more_reports

The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

Report of FDA Drug Approval Delay is 'Likely Noise': Analyst

Research Report
  ()
Disc Medicine Inc.'s (IRON:NASDAQ) chances of bitopertin getting approved remain unaltered by the claims in a recent article, noted an H.C. Wainwright & Co. report. Read on to learn the reasons behind this opinion of the investment bank.
Tags: Biotechnology / Pharmaceuticals

Analysts Highlight Notable H1/26 Catalysts in Biotech

Research Report
  ()
Despite the overall run-up in biotech names last year, the sector still offers "several attractive H1/26 catalyst set-ups, noted an RBC Capital Markets report. Find out which upcoming events the analysts like the most and the least.
Tags: Biotechnology / Pharmaceuticals

AI Collaboration Expands to Accelerate Cancer Drug Discovery

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) has broadened its partnership with Variational AI to refine next-generation ATR inhibitors using generative AI. The agreement aims to streamline lead optimization for the company's kt-5000 series of small-molecule cancer drug candidates.
Tags: Life Sciences Tools & DiagnosticsBiotechnology / Pharmaceuticals

Expanded AI Collaboration Advances Optimization of Cancer Drug Candidates

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) has expanded its partnership with Variational AI to advance optimization of its kt-5000 ATR inhibitor series. Learn how the agreement deepens the company's use of generative AI to refine small-molecule drug candidates and accelerate preclinical selection.
Tags: Biotechnology / PharmaceuticalsLife Sciences Tools & Diagnostics

Clean-Tech Co. Looks Forward to Massive Market Breakthroughs in 2026

  ()
BioLargo Inc.'s (BLGO:OTCQX) President and Chief Executive Officer Dennis P. Calvert notes the company is looking forward to its part in "what may be one of the largest infrastructure and technology investment cycles in history."
Tags: TechnologyBiotechnology / PharmaceuticalsSpecial SituationsClean Energy

Clean-Tech Firm Anticipates Major Market Advancements in 2026

  ()
Dennis P. Calvert, President and CEO of BioLargo Inc. (BLGO:OTCQX), mentions that the company is eager to participate in "what may be one of the largest infrastructure and technology investment cycles in history."
Tags: Clean EnergyBiotechnology / PharmaceuticalsTechnology

Mineral Investor Chen Lin Argues Silver Moving From Bullion to Physical Asset, Reveals Picks

  ()
Seasoned minerals investor Chen Lin argues silver's 50-year breakout is not a routine cycle but a transition from bullion to a tightening "critical minerals" market. Read on to see what some of his top picks are, including one biotech company he thinks could be the next Eli Lilly.
Tags: SilverBiotechnology / Pharmaceuticals

Market Experts Uncover Excellent Buys During December 'Silly Season' Tax Selloff

  ()
Every December, tax-loss selling tends to exert downward pressure on certain stocks as investors aim to offset capital gains. Streetwise Reports asked some of its frequent contributors to add their own thoughts on the other "holiday season" and give their own picks for good bargains.
Tags: Special SituationsTechnologyOil & Gas - Exploration & ProductionSilverGoldCopperBiotechnology / PharmaceuticalsBase MetalsCritical Metals

NanoPortal GLP-1 Implant: Adherence Arbitrage Opportunity

  ()
Vivani offers a unique arbitrage opportunity on GLP-1 adherence in a massive addressable market. The NanoPortal technology is now clinically validated via the NPM-115 trial, and the company is fully funded to launch its high-value semaglutide program, including lead asset NPM-139, in 2026. Risks regarding future dilution and regulatory execution remain elevated, but the market capitalization undervalues the potential of the platform. We view current valuation as an entry point for risk-tolerant investors and reiterate our $7.00 price target
Tags: Biotechnology / Pharmaceuticals

Data on 2 Drugs, Identified Via AI, Shared at Conference

Research Report
  ()
Rakovina Therapeutics Inc.'s (RKV:TSX.V) preclinical ATR inhibitors, Compound A and Compound C, exhibit similarities to two clinical-stage drugs in the same class, noted a Leede Financial Inc. report.
Tags: Biotechnology / Pharmaceuticals

AI Breakthroughs Drive New Momentum in Oncology Research

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) reported financial and operational results for Q3, detailing continued progress across its AI-enabled DNA Damage Response programs. The company highlighted new scientific data, expanded collaborations, and increased visibility at major oncology conferences.
Tags: Biotechnology / Pharmaceuticals

Biotech Co.'s Q3/25 Progress on Lead Programs Steady

Research Report
  ()
Alto Neuroscience Inc.'s (ANRO:NYSE) clinical execution and regulatory momentum advance the firm's biomarker-guided precision psychiatry pipeline, noted an H.C. Wainwright & Co. report.
Tags: Biotechnology / Pharmaceuticals

Biotech Co. Advances Precision Psychiatry Breakthrough Pipeline While Analysts' Sentiment Remains Positive

  ()
Alto Neuroscience Inc. (ANRO:NYSE) continues moving its clinical programs forward, receives regulatory clarity and raises US$50 million, during the past four months. Read on for analysts' thoughts on this biopharma.
Tags: Biotechnology / Pharmaceuticals

AI Identifies Preclinical Cancer Compounds With Potential to Reach the Brain

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) presented new data at the 2025 Society for Neuro-Oncology Annual Meeting on its PARP1-selective inhibitors, with central nervous system penetration. The findings demonstrated how Rakovina's AI-powered discovery platform identified promising drug candidates designed to target brain-involved cancers.
Tags: Biotechnology / Pharmaceuticals

How Do Analysts Rate This Biopharma Targeting Psychiatric Disorders

  ()
Alto Neuroscience Inc. (ANRO:NYSE) is developing drug candidates for psychiatric and neurological disorders, utilizing a precision approach rather than a one-size-fits-all method. Read to find out how analysts rate this company.
Tags: Biotechnology / Pharmaceuticals

US$12 Billion RNA Deal Triggers Sector Shakeup

  ()
Avidity Biosciences Inc. (RNA:NASDAQ) reported Q3 results alongside news of its US$12 billion acquisition by Novartis. The deal comes as three RNA drugs approach major regulatory filings through 2026.
Tags: Biotechnology / Pharmaceuticals

Lead Drug Faces Uncertain FDA Path After Phase 3 Miss

  ()
aTyr Pharma Inc. (ATYR:NASDAQ) is seeking regulatory clarity following mixed Phase 3 results for its lead candidate efzofitimod in pulmonary sarcoidosis. The company expects feedback from the FDA in the first quarter of 2026 to help determine a potential path forward.
Tags: Biotechnology / Pharmaceuticals

Preclinical Compounds Perform Better Than Existing Drugs

Research Report
  ()
Rakovina Therapeutics Inc.'s (RKV:TSX.V) AI-designed Compounds A, B and C demonstrated the same ATR blocking activity as three of Big Pharma's existing, clinical-stage drugs but at much lower concentrations, noted a Leede Financial Inc. report.
Tags: Biotechnology / Pharmaceuticals

Breakthrough Pill Cuts Bad Cholesterol by Nearly 60% in Major Trials

  ()
Merck & Co. Inc. (MRK:NYSE) announced that its investigational oral PCSK9 inhibitor, enlicitide, achieved significant LDL-C reductions in two pivotal Phase 3 studies presented at the American Heart Association Scientific Sessions. The once-daily pill demonstrated efficacy comparable to injectable therapies, marking a major step forward in cholesterol management.
Tags: Biotechnology / Pharmaceuticals

Biotech to Fast Track Phase 3 Depression Trial

Research Report
  ()
Alto Neuroscience Inc. (ANRO:NYSE) intends to carry out this newly added study, supported by a recent financing, and the previously planned Phase 2b trial simultaneously, noted a William Blair report.
Tags: Biotechnology / Pharmaceuticals

Co. Speeds Up Development of New Drug for Depression

Research Report
  ()
Alto Neuroscience Inc. (ANRO:NYSE) plans Phases 2b and 3 trials of its asset, ALTO-207, in treatment-resistant depression, noted a Jefferies report.
Tags: Biotechnology / Pharmaceuticals

2 Key Catalysts Ahead for Developer of Psych Drugs

Research Report
  ()
Alto Neuroscience Inc. (ANRO:NYSE) expects to release topline trial data in 2025 and commence a separate study in 2026, noted an H.C. Wainwright & Co. report.
Tags: Biotechnology / Pharmaceuticals

Price Target on Psychiatric Drug Biotech Boosted 200%

Research Report
  ()
Alto Neuroscience Inc. (ANRO:NYSE) completed a US$50 million equity raise and announced plans to accelerate development of its recently acquired asset in treatment-resistant depression, noted a Wedbush report.
Tags: Biotechnology / Pharmaceuticals

US Biopharma In-Licenses 3 New Assets

Research Report
  ()
Zenas BioPharma Inc.'s (ZBIO:NASDAQ) target price is increased 14% to reflect the Phase 3 investigative multiple sclerosis drug included in this recent deal, noted a Wedbush report.
Tags: Biotechnology / Pharmaceuticals

Showing Results: 1 to 25 of 42 Next